Takeda presents new data showing mezagitamab sustained effect on kidney function 18 months after treatment in primary IgA nephropathy: Osaka, Japan Monday, November 10, 2025, 15:0 ...
‘Both GLP-1s and exercise can have significant, but somewhat different, impacts on cardiovascular health. Large trials of GLP ...
Sometimes it is hard to know what is going on inside your body. Though, stomach pain and/or discomfort can be alarming but ...
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback